RedHill's Opaganib Shows Positive Preclinical Results in Neuroblastoma and Triple-Negative Breast Cancer

summarizeSummary

RedHill Biopharma announced positive preclinical data for its drug candidate Opaganib in neuroblastoma and triple-negative breast cancer, suggesting enhanced chemotherapy efficacy and anti-tumor immunity.

check_boxKey Events

• Positive Preclinical Data

  Opaganib showed positive effects as an add-on therapy in models of neuroblastoma (NB) and triple-negative breast cancer (TNBC) at the AACR 2026 Annual Meeting.

• Enhanced Chemotherapy Efficacy

  In neuroblastoma, Opaganib enhanced the therapeutic efficacy of the oxaliplatin + doxorubicin chemotherapy combination by directly destabilizing n-Myc.

• Augmented Anti-Tumor Immunity

  In triple-negative breast cancer, Opaganib pre-treatment potentiated STING-mediated effects, potentially augmenting anti-tumor immunity.

• Orphan Drug Designation

  Opaganib holds FDA Orphan Drug and Rare Pediatric Disease designations for the treatment of neuroblastoma.

auto_awesomeAnalysis

This filing provides positive preclinical data for Opaganib, a key pipeline asset, in two difficult-to-treat cancers. While preclinical, these results offer a potential long-term value driver and a positive development amidst the company's recent Nasdaq delisting notice. The data suggests Opaganib could enhance chemotherapy efficacy and augment anti-tumor immunity, supporting its continued development and potential for an Orphan Drug Priority Review Voucher.